Our finding of differential expression of LOXL2, LOXL3 and LOXL4 in IPF tissue suggests that therapeutic targeting of additional LOXL family members is required to inhibit pathologic collagen cross-linking. The gene discussed is LOXL4; the disease is idiopathic pulmonary fibrosis.